Redx celebrates exciting breakthrough

MERSEYSIDE-based drug development company Redx Pharma is celebrating a breakthrough in its research into the treatments of cancers, including pancreative, breast and head and neck cancer.

It has announced it has reached pre-clinical proof of the concept stage with an advanced oncology lead, with has the potential to tackle the hard-to-treat cancers.

Dr Neil Murray, CEO of Redx, said: “We’re very pleased to have reached pre-clinical proof of concept with this very promising programme. The cancers it has the potential to tackle are some of the most hard-to-treat.

See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.